Comparison of the anti-tumor activity of native, secreted, and membrane-bound LIGHT in mouse tumor models

International Immunopharmacology

Volumn 10, Issue 1, 2010, Pages 26-33

  Morishige, Tomohiro ^a   Yoshioka, Yasuo ^a   Tanabe, Aya ^a   Yao, Xinglei ^a   Mizuguchi, Hiroyuki ^a,b   Tsunoda, Shin ichi ^b   Tsutsumi, Yasuo ^a,b   Mukai, Yohei ^a   Okada, Naoki ^a   Nakagawa, Shinsaku ^a  

^a OSAKA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

Adenovirus vector; Cancer gene therapy; Cytokine; LIGHT; Lymphotoxin

Indexed keywords

ADENOVIRUS VECTOR; TUMOR NECROSIS FACTOR DERIVATIVE; TUMOR NECROSIS FACTOR SUPERFAMILY MEMBER LIGHT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR MODEL;

ADENOVIRIDAE; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; GENE THERAPY; GENETIC VECTORS; HT29 CELLS; HUMANS; MELANOMA, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PROTEIN ENGINEERING; TUMOR BURDEN; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14;

EID: 73149102515     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.09.014     Document Type: Article

References (30)

1. Mauri D.N., Ebner R., Montgomery R.I., Kochel K.D., Cheung T.C., et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 8 (1998) 21-30
2. Harrop J.A., McDonnell P.C., Brigham-Burke M., Lyn S.D., Minton J., Tan K.B., et al. Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J Biol Chem 273 (1998) 27548-27556
3. Murphy M., Walter B.N., Pike-Nobile L., Fanger N.A., Guyre P.M., Browning J.L., et al. Expression of the lymphotoxin beta receptor on follicular stromal cells in human lymphoid tissues. Cell Death Differ 5 (1998) 497-505
4. Wang J., Foster A., Chin R., Yu P., Sun Y., Wang Y., et al. The complementation of lymphotoxin deficiency with LIGHT, a newly discovered TNF family member, for the restoration of secondary lymphoid structure and function. Eur J Immunol 32 (2002) 1969-1979
5. Rooney I.A., Butrovich K.D., Glass A.A., Borboroglu S., Benedict C.A., Whitbeck J.C., et al. The lymphotoxin-beta receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells. J Biol Chem 275 (2000) 14307-14315
6. Yu P., Lee Y., Liu W., Chin R.K., Wang J., Wang Y., et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 5 (2004) 141-149
7. Stopfer P., Mannel D.N., and Hehlgans T. Lymphotoxin-beta receptor activation by activated T cells induces cytokine release from mouse bone marrow-derived mast cells. J Immunol 172 (2004) 7459-7465
8. Tamada K., Shimozaki K., Chapoval A.I., Zhai Y., Su J., Chen S.F., et al. LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol 164 (2000) 4105-4110
9. Wang J., Lo J.C., Foster A., Yu P., Chen H.M., Wang Y., et al. The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. J Clin Invest 108 (2001) 1771-1780
10. Fan Z., Yu P., Wang Y., Fu M.L., Liu W., Sun Y., et al. NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors. Blood 107 (2006) 1342-1351
11. Yu P., Lee Y., Wang Y., Liu X., Auh S., Gajewski T.F., et al. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol 179 (2007) 1960-1968
12. Schneider P., Holler N., Bodmer J.L., Hahne M., Frei K., Fontana A., et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 187 (1998) 1205-1213
13. Grell M., Douni E., Wajant H., Lohden M., Clauss M., Maxeiner B., et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83 (1995) 793-802
14. Esch F.S., Keim P.S., Beattie E.C., Blacher R.W., Culwell A.R., Oltersdorf T., et al. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 248 (1990) 1122-1124
15. Subramanian S.V., Fitzgerald M.L., and Bernfield M. Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J Biol Chem 272 (1997) 14713-14720
16. Gregory M.S., Saff R.R., Marshak-Rothstein A., and Ksander B.R. Control of ocular tumor growth and metastatic spread by soluble and membrane Fas ligand. Cancer Res 67 (2007) 11951-11958
17. Anand S., Wang P., Yoshimura K., Choi I.H., Hilliard A., Chen Y.H., et al. Essential role of TNF family molecule LIGHT as a cytokine in the pathogenesis of hepatitis. J Clin Invest 116 (2006) 1045-1051
18. Morel Y., Schiano de Colella J.M., Harrop J., Deen K.C., Holmes S.D., Wattam T.A., et al. Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor. J Immunol 165 (2000) 4397-4404
19. Mizuguchi H., and Kay M.A. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther 9 (1998) 2577-2583
20. Mizuguchi H., and Kay M.A. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum Gene Ther 10 (1999) 2013-2017
21. Mizuguchi H., and Hayakawa T. Enhanced antitumor effect and reduced vector dissemination with fiber-modified adenovirus vectors expressing herpes simplex virus thymidine kinase. Cancer Gene Ther 9 (2002) 236-242
22. Maizel Jr. J.V., White D.O., and Scharff M.D. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 36 (1968) 115-125
23. Okada Y., Okada N., Mizuguchi H., Takahashi K., Hayakawa T., Mayumi T., et al. Optimization of antitumor efficacy and safety of in vivo cytokine gene therapy using RGD fiber-mutant adenovirus vector for preexisting murine melanoma. Biochim Biophys Acta 1670 (2004) 172-180
24. Yu K.Y., Kwon B., Ni J., Zhai Y., Ebner R., Kwon B.S., et al. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 274 (1999) 13733-13736
25. Fearon E.R., Itaya T., Hunt B., Vogelstein B., and Frost P. Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res 48 (1988) 2975-2980
26. Tanaka K., Gorelik E., Watanabe M., Hozumi N., and Jay G. Rejection of B16 melanoma induced by expression of a transfected major histocompatibility complex class I gene. Mol Cell Biol 8 (1988) 1857-1861
27. Yu P., and Fu Y.X. Targeting tumors with LIGHT to generate metastasis-clearing immunity. Cytokine Growth Factor Rev 19 (2008) 285-294
28. Loeffler M., Le'Negrate G., Krajewska M., and Reed J.C. Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proc Natl Acad Sci U S A 104 (2007) 12879-12883
29. Shaikh R.B., Santee S., Granger S.W., Butrovich K., Cheung T., Kronenberg M., et al. Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction. J Immunol 167 (2001) 6330-6337
30. Lukashev M., LePage D., Wilson C., Bailly V., Garber E., Lukashin A., et al. Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy. Cancer Res 66 (2006) 9617-9624